Advertisement

Radiolabeled Antibody Therapy of Human B Cell Lymphomas

  • Oliver W. Press
  • Janet F. Eary
  • Christopher C. Badger
  • Paul J. Martin
  • Frederick R. Appelbaum
  • Wil B. Nelp
  • Ron Levy
  • Richard Miller
  • Darrell Fisher
  • Dana Matthews
  • Irwin D. Bernstein
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 303)

Abstract

Modern chemotherapy regimens are capable of curing the majority of patients with newly diagnosed diffuse aggressive lymphomas1, but few patients with low-grade lymphomas or relapsed aggressive lymphomas can be cured with conventional therapy. High dose chemoradiotherapy in conjunction with marrow transplantation affords long term disease-free survival for approximately 25% of such patients2,3, but toxicity is formidable and post-transplant relapse and treatment-related complications result in the death of most such patients. Targeted radiotherapy using radiolabeled antibodies (RAb) offers a potentially effective new approach for refractory malignancies as demonstrated by a variety of animal and human studies4–13. In this report we summarize our experience administering radiolabeled anti-B cell antibodies to patients with refractory non-Hodgkin’s lymphomas in a phase I dose escalation trial.

Keywords

Aggressive Lymphoma Massive Splenomegaly Autologous Marrow Radiation Therapy Oncology Group Study Refractory Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. Klimo. Chemotherapy for aggressive non-Hodgkin’s lymphomas, in “Cancer: Principles and Practice of Oncology-Update 2 (no. 9),” pp. 1–12, De Vita VT, Hellman S, Rosenberg SA, eds., Lippincott, Philadelphia (1988).Google Scholar
  2. 2.
    F. Appelbaum, K. Sullivan, C. D. Buckner, and E. D. Thomas, Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation, J. Clin. Oncol. 5: 1340–1347 (1987).PubMedGoogle Scholar
  3. 3.
    F. B. Petersen, F. R. Appelbaum, R. Hill, L. D. Fisher, C. L. Bigelow, J. E. Sanders, K. M. Sullivan, W. I. Bensinger, R. P. Witherspoon, R. Storb, R. A. Clift, A. Fefer, O. W. Press, P. L. Weiden, J. Singer, E. D. Thomas, and C. D. Buckner, Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle, J. Clin. Oncol. 8: 638–647 (1990).PubMedGoogle Scholar
  4. 4.
    C. Badger, K. Krohn, A. Peterson, and I. D. Bernstein, Experimental radiotherapy of murine lymphoma with I-131-labeled anti-Thy 1.1 monoclonal antibody, Cancer Res. 45: 1536–1544 (1985).PubMedGoogle Scholar
  5. 5.
    C. Badger, K. Krohn, H. Shulman, and I. D. Bernstein, Experimental radioimmunotherapy of murine lymphoma with I-131-labeled anti-T cell antibodies,Cancer Res. 46: 6223–6228 (1986).PubMedGoogle Scholar
  6. 6.
    F. R. Appelbaum, P. Brown, and B. Sandmaier, Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation, Blood (in press).Google Scholar
  7. 7.
    S. Order, G. Stillwagon, and J. Klein, Iodine-131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study, J. Clin. Oncol. 3: 1573–1582 (1985).PubMedGoogle Scholar
  8. 8.
    R. Lenhard, S. Order, and J. Spunberg, Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin’s Disease, J. Clin. Oncol. 3: 1296–1300 (1985).PubMedGoogle Scholar
  9. 9.
    S. Rosen, A. Zimmer, and R. Goldman-Leikin, Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an I-131-labeled monoclonal antibody: An Illinois Cancer Council study, J. Clin. Oncol. 5: 562–573 (1987).PubMedGoogle Scholar
  10. 10.
    S. DeNardo, G. DeNardo, and L. O’Grady, Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, Antibod. Immunoconjugates Radiopharmaceut. 1: 17–33 (1988).Google Scholar
  11. 11.
    A. Epenetos, A. Munro, and S. Stewart, Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies, J. Clin. Oncol. 5: 1890–1899 (1987).PubMedGoogle Scholar
  12. 12.
    L. Lashford, D. Jones, and J. Pritchard, Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma, NCI Monogr. 3: 53–57 (1987).PubMedGoogle Scholar
  13. 13.
    O. W. Press, J. Eary, C. C. Badger, F. A. Appelbaum, P. J. Martin, R. Levy, R. Miller, S. Brown, W. B. Nelp, K. A. Krohn, D. Fisher, K. De Santes, B. Porter, P. Kidd, E. D. Thomas, and I. D. Bernstein, Treatment of patients with refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody, J. Clin. Onc. 7: 1027–1038 (1989).Google Scholar
  14. 14.
    J. Eary, O. Press, C. Badger, P. Martin, F. Appelbaum, K. Krohn, R. Levy, S. Brown, R. Miller, D. Fisher, W. Nelp, and I. Bernstein, Imaging and treatment of B-cell lymphoma, J. Nucl. Med. 31:1257–1268 (1990).PubMedGoogle Scholar
  15. 15.
    Society of Nuclear Medicine: MIRD Primer for absorbed dose calculation, Washington D.C., Society of Nuclear Medicine (1988).Google Scholar
  16. 16.
    J. A. Bianco, B. Sandmaier, P. A. Brown, C. Badger, I. Bernstein, J. Eary, L. Durack, F. Schuening, R. Storb, and F. Appelbaum, Specific marrow localization of an I-131-labeled anti-myeloid antibody in normal dogs: effects of a “cold” antibody pretreatment dose on marrow localization, Exp. Hematol. 17: 929–934 (1989).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Oliver W. Press
    • 1
    • 2
    • 3
    • 4
    • 5
  • Janet F. Eary
    • 1
    • 2
    • 3
    • 4
    • 5
  • Christopher C. Badger
    • 1
    • 2
    • 3
    • 4
    • 5
  • Paul J. Martin
    • 1
    • 2
    • 3
    • 4
    • 5
  • Frederick R. Appelbaum
    • 1
    • 2
    • 3
    • 4
    • 5
  • Wil B. Nelp
    • 1
    • 2
    • 3
    • 4
    • 5
  • Ron Levy
    • 1
    • 2
    • 3
    • 4
    • 5
  • Richard Miller
    • 1
    • 2
    • 3
    • 4
    • 5
  • Darrell Fisher
    • 1
    • 2
    • 3
    • 4
    • 5
  • Dana Matthews
    • 1
    • 2
    • 3
    • 4
    • 5
  • Irwin D. Bernstein
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Departments of Medicine, Nuclear Medicine, and PediatricsUniversity of WashingtonSeattleUSA
  2. 2.The Fred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.School of MedicineStanford UniversityStanfordUSA
  4. 4.The Battelle Pacific Northwest LaboratoriesRichlandUSA
  5. 5.IDEC Pharmaceuticals CorporationMountain ViewUSA

Personalised recommendations